» Articles » PMID: 35344554

Survival Analysis of Pathway Activity As a Prognostic Determinant in Breast Cancer

Overview
Specialty Biology
Date 2022 Mar 28
PMID 35344554
Authors
Affiliations
Soon will be listed here.
Abstract

High throughput biology enables the measurements of relative concentrations of thousands of biomolecules from e.g. tissue samples. The process leaves the investigator with the problem of how to best interpret the potentially large number of differences between samples. Many activities in a cell depend on ordered reactions involving multiple biomolecules, often referred to as pathways. It hence makes sense to study differences between samples in terms of altered pathway activity, using so-called pathway analysis. Traditional pathway analysis gives significance to differences in the pathway components' concentrations between sample groups, however, less frequently used methods for estimating individual samples' pathway activities have been suggested. Here we demonstrate that such a method can be used for pathway-based survival analysis. Specifically, we investigate the pathway activities' association with patients' survival time based on the transcription profiles of the METABRIC dataset. Our implementation shows that pathway activities are better prognostic markers for survival time in METABRIC than the individual transcripts. We also demonstrate that we can regress out the effect of individual pathways on other pathways, which allows us to estimate the other pathways' residual pathway activity on survival. Furthermore, we illustrate how one can visualize the often interdependent measures over hierarchical pathway databases using sunburst plots.

Citing Articles

Pathway analysis through mutual information.

Jeuken G, Kall L Bioinformatics. 2024; 40(1).

PMID: 38195928 PMC: 10783954. DOI: 10.1093/bioinformatics/btad776.


PATH-SURVEYOR: pathway level survival enquiry for immuno-oncology and drug repurposing.

Obermayer A, Chang D, Nobles G, Teng M, Tan A, Wang X BMC Bioinformatics. 2023; 24(1):266.

PMID: 37380943 PMC: 10303868. DOI: 10.1186/s12859-023-05393-y.

References
1.
Moasser M . The oncogene HER2: its signaling and transforming functions and its role in human cancer pathogenesis. Oncogene. 2007; 26(45):6469-87. PMC: 3021475. DOI: 10.1038/sj.onc.1210477. View

2.
Uno H, Cai T, Pencina M, DAgostino R, Wei L . On the C-statistics for evaluating overall adequacy of risk prediction procedures with censored survival data. Stat Med. 2011; 30(10):1105-17. PMC: 3079915. DOI: 10.1002/sim.4154. View

3.
Griss J, Viteri G, Sidiropoulos K, Nguyen V, Fabregat A, Hermjakob H . ReactomeGSA - Efficient Multi-Omics Comparative Pathway Analysis. Mol Cell Proteomics. 2020; 19(12):2115-2125. PMC: 7710148. DOI: 10.1074/mcp.TIR120.002155. View

4.
Parker J, Mullins M, Cheang M, Leung S, Voduc D, Vickery T . Supervised risk predictor of breast cancer based on intrinsic subtypes. J Clin Oncol. 2009; 27(8):1160-7. PMC: 2667820. DOI: 10.1200/JCO.2008.18.1370. View

5.
Altman N, Krzywinski M . The curse(s) of dimensionality. Nat Methods. 2018; 15(6):399-400. DOI: 10.1038/s41592-018-0019-x. View